Efficacy and safety of sensor augmented insulin pump therapy withlow-glucose suspend feature in older adults : a retrospective study in Bogota, Colombia
Ver / Descargar
Fecha
2021Autor(es)
Morros-González, EllyGómez, Ana María
Henao Carrillo, Diana Cristina
Ursida, Valentina
Serrano, Sergio
Rondón Sepúlveda, Martín Alonso
Muñoz Velandia, Oscar Mauricio
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Envejecimiento
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Medicina Interna
Tipo
Artículo de revista
ISSN
1871-4021
Compartir este registro
Citación
Documentos PDF
Abstract
Background and aims:The literature has supported the efficacy and safety of insulin pump therapy inyoung adults diagnosed with type 1 diabetes (DM1). However, there is limited evidence in older adultswith DM1 and DM2.Methods:A retrospective cohort study was conducted in patients≥60 years-old with DM1 and DM2,who started Sensor Augmented Insulin Pump therapy with low-glucose suspend feature (SAPþLGS) atHospital Universitario San Ignacio diabetes center in Bogotá, Colombia. Patients were evaluated between2009 and 2019 and were treated with Paradigm VEO or Medtronic MiniMed 640 insulin pumps andcontinuous glucose monitoring system. Glycated hemoglobin (A1c), severe hypoglycemia and hypogly-cemia unawareness were assessed at least every 3 months, and hospitalizations and ketoacidosis epi-sodes incidence were assessed yearly.Results:36 patients were analyzed, (67.36±4.88 years-old) (body mass index 25.48±4.61 kg/m2). Themost common indications for starting SAPþLGS were hypoglycemia (58.3%), high glycemic variability(25.0%) and poor metabolic control (16.7%). 26 patients used VEO (72.2%) whereas 27.8% started 640insulin pump. Data from 32 participants showed A1c decreased from 8.57±1.73% to 7.42±0.96 after ayear of therapy (Mean difference 1.15%, p<0.05); 28.12% reached A1c levels<7% and 42.85%<7.5%.There was a significant decrease in the proportion of patients with at least one severe hypoglycemia (56.7vs 3.3%), one or more hospitalizations (20 vs 3.3%), and hypoglycemia unawareness after thefirst year offollow-up (p<0.05).Conclusions:These results suggest that SAPþLGS is safe and effective in people 60 years or older afterone year of therapy. Future randomized clinical trials are needed in the elderly.
Keywords
Sensor augmented insulin pump therapyLow-glucose suspend function
Continuous subcutaneous insulin infusion
Hypoglycemia
Aged
Elderly
Cobertura espacial (Ciudades)
Bogotá (Colombia)Cobertura espacial
ColombiaEnlace al recurso
https://login.ezproxy.javeriana.edu.co/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S187140212100059X&lang=es&site=eds-liveFuente
Diabetes & Metabolic Syndrome : Clinical Research & Reviews; Volumen 15 , Páginas 649 - 653 (2021)
Estadísticas Google Analytics
Colecciones
- Artículos [274]